Review of research progress on intestinal microbiota based on metabolism and inflammation for depression
- 10 March 2024
- journal article
- review article
- Published by Springer Nature in Archives of Microbiology
- Vol. 206 (4) , 1-11
Abstract
Depression is a prevalent mental illness, affecting a significant portion of the global population. Recent research has highlighted the crucial role of the gut microbiota in both metabolic and central nervous health. By reviewing literature from various databases, including Pubmed, Science Direct, Web of Science, and Scopus, spanning the years 2005–2023, a comprehensive search was conducted using keywords such as "Depression" and "Gut Microbiota". The gut microbiota acts as a "second brain" in humans and can communicate bidirectionally with the brain through the Brain-gut-microbiota axis pathway. This communication involves the immune and nervous systems. However, there are challenges in detecting and treating depression effectively. To address these limitations, researchers have been exploring the relationship between gut microbiota and depression. Studies have shown that gut microbial metabolites, such as lipopolysaccharides and short-chain fatty acids, can induce pro-inflammatory cytokines that contribute to neuroinflammation and increase the risk of depression. The kynurenine pathway, triggered by gut microbial metabolites, has also been associated with neuroinflammation. Thus, investigating these microbial metabolites can provide insights into depression treatment. This review focuses on analyzing the connection between gut microbial metabolites, inflammation, and depression. It explores novel mechanisms contributing to depression, specifically focusing on the mediation of inflammation through the release of pro-inflammatory cytokines. The objective is to provide valuable insights into the mechanisms underlying depression and to propose potential treatments.Keywords
This publication has 72 references indexed in Scilit:
- Cutting Edge: A Cullin-5–TRAF6 Interaction Promotes TRAF6 Polyubiquitination and Lipopolysaccharide SignalingThe Journal of Immunology, 2016
- From gut dysbiosis to altered brain function and mental illness: mechanisms and pathwaysMolecular Psychiatry, 2016
- Spine synapse remodeling in the pathophysiology and treatment of depressionNeuroscience Letters, 2015
- Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorderBrain, Behavior, and Immunity, 2015
- CD14, TLR4 and TRAM Show Different Trafficking Dynamics During LPS StimulationTraffic, 2015
- Putative Neuroprotective and Neurotoxic Kynurenine Pathway Metabolites Are Associated with Hippocampal and Amygdalar Volumes in Subjects with Major Depressive DisorderNeuropsychopharmacology, 2014
- Acute neural effects of selective serotonin reuptake inhibitors versus noradrenaline reuptake inhibitors on emotion processing: Implications for differential treatment efficacyNeuroscience & Biobehavioral Reviews, 2013
- The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression.2008
- Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behaviorPsychoneuroendocrinology, 2007
- Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation clusterTrends in Immunology, 2002